INORGANIC ION EXCHANGERS FOR 213BI GENERATORS

铋是一种释放α的放射性核素，在治疗某些类型的癌症方面有潜在的用途。辐射在消灭癌细胞方面效率低下，在人体组织中的辐射范围只有几毫米。相比之下，α粒子摧毁癌细胞的效率是α粒子的数千倍，其范围只有几μ m，对周围组织的损伤较小。为了制造213Bi发生器，需要开发新的辐射稳定离子交换器，将213Bi从母体核素225Ac中分离出来。两类磷酸锆已经从镅（锕的替代物）中获得了很好的铋分离，这些结果将在第一阶段得到改善。离子交换动力学也将被评估，并确定合适的洗脱液。第二阶段将在阿贡国家实验室使用放射性同位素来优化213Bi/225Ac的分离，进一步的材料将在德克萨斯A&M大学合成，213Bi原型发电机的设计和制造将在Lynntech与芝加哥大学医院协商后进行。该团队利用分离科学的进步来构建用于临床测试的用户友好型213Bi发生器。制造213Bi发生器将极大地促进对α -放射放射性核素治疗用途的研究，因为它提供了纯213Bi的来源，使α -治疗可以在常规基础上使用，而不是用于研究试验。建议的商业应用：α粒子比β或γ粒子更能有效地摧毁癌细胞，而且对周围健康组织的损害也更小。生产供应213Bi的发生器将使放射免疫疗法（RIT）取得重大进展，使α发射体能够安全地用于远离α发射同位素供应来源的医疗中心，从而促进基础癌症研究。一旦被批准用于医疗用途，这种产品的市场每年将达到数百万美元。

213Bi is an alpha-emitting radionuclide with potential uses in the treatment of certain types of cancer. Beta radiation is inefficient at destroying cancer cells and has a range of several mm in body tissue. By contrast, alpha particles are thousands of times more efficient at destroying cancer cells and have a range of only a few mu m, resulting in less peripheral tissue damage. New radiation-stable ion exchangers need to be developed to cleanly separate 213Bi from the parent nuclide, 225Ac, to allow the manufacture of a 213Bi generator. Two classes of zirconium phosphonates have already achieved good bismuth separations from americium (a surrogate for actinium) and these results will be improved upon during Phase I. Ion exchange kinetics will also be evaluated and suitable eluants identified. Phase II will use radioisotopes at Argonne National Laboratory to optimize the 213Bi/225Ac separation, further materials will be synthesized at Texas A&M University, and the design and fabrication of a prototype 213Bi generator will be carried out at Lynntech in consultation with the University of Chicago Hospital. This team allows advances in separation science to be utilized to construct a user-friendly 213Bi generator for use in clinical testing. Manufacture of a 213Bi generator will greatly facilitate research into the therapeutic uses of alpha-emitting radionuclides by providing a source of pure 2i3Bi, allowing alpha therapy to be used on a routine basis rather than in research trials. PROPOSED COMMERCIAL APPLICATIONS: Alpha particles are more effective at destroying cancer cells than beta or gamma particles and also cause less damage to surrounding healthy tissue. Production of a generator to supply 213Bi would allow a major advance in radioimmunotherapy (RIT) by enabling alpha emitters to be safely used at medical centers distant from the source of supply of the alpha emitting isotopes, thus facilitating basic cancer research. 0nce approved for medical use, the market for such a product would be millions of dollars per year.